Experience With Rituximab in Scleroderma: Results From a 1-Year, Proof-of-Principle Study
Daoussis D, Liossis SN, Tsamandas AC, et al
Rheumatology (Oxford). 2010;49:271-280
Background
Multiple drugs have been tried in scleroderma to improve both skin disease and pulmonary disease. However, most of these studies have failed to show significant benefit. In an open-label study, Daoussis and colleagues investigated the effect of the B-cell directed agent rituximab in improving pulmonary function and skin disease in scleroderma.
The entire article can be found on Medscape.
To view the entire article (and all other content on Medscape from WebMD), a one-time registration is needed, which is free of charge.
Experience With Rituximab in Scleroderma: Results From a 1-Year, Proof-of-Principle Study - http://www.medscape.com/viewarticle/717883
Home 
Research Recently Published Articles Experience With Rituximab in Scleroderma
Research Recently Published Articles Experience With Rituximab in Scleroderma
Experience With Rituximab in Scleroderma
Newsflash
| Ulcer Treatment Questionnaire |
Scleroderma Australia is concerned about the cost of dressings for scleroderma patients, many of whom have chronic skin conditions. Therefore the association would like to petition the Federal Government to consider either subsidization or reimbursement for ulcer treatments and dressings. To do this we need more information on the type of dressings patients use, how often you use them and how much it costs you. Please take a few minutes to fill in the following questionnaire so that we can take action on this issue. |
